Humana maintains a healthy balance sheet, in our opinion. Most of its cash and investments ($24 billion as of mid-2024) is held at its subsidiaries, though, and the company aims to hold about $500 ...

Explore Novotech CEO John Moller's insights on the company's global expansion, commitment to diversity, and innovative ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...

UnitedHealth has dropped nearly 50% amid headwinds, but strong fundamentals, margin stability, and low valuation signal ...

As retail pharmacy giants like CVS Health and Walgreens look to find their footing, they could find opportunities customizing ...

U.S. prices for newly-launched pharmaceuticals more than doubled last year compared to 2021, as companies leveraged ...

Rep. Preston Stinson (R-Edmond) and Sen. Brent Howard (R-Altus) released a joint statement following Governor Kevin Stitt’s ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

By elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns ...

A new study finds that CivicaScript, a not-for-profit drug manufacturer in the US, can reliably supply essential generic ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...

The likely disappearance of the drugstore chain has customers on edge. For many, the chain had become a trusted source for ...